Large-Cap Pharma Down Across the Board as Market Reassesses Drug Pipelines

Major biotech and pharma stocks fall; insiders at some names showing contrarian strength.

Photograph of David A. Ricks · Virginia Office of the Governor · CC BY 4.0. Cover illustration by InsiderBuying.com.

Key points

PFE, JNJ, MRK, and AMGN all fell between 1.3% and 1.8% on October 24th, 2026.
PFE carries a Very Strong Insider Score, per our Insider Score feed, despite today's decline.
Sector-wide selloff may reflect profit-taking or reassessment of late-stage pipeline catalysts heading into year-end.

Large-cap pharma and biotech stocks retreated across the board on October 24th, 2026, with major names including Pfizer (PFE), Johnson & Johnson (JNJ), Merck (MRK), and Amgen (AMGN) posting losses between 1.3% and 1.8%. The broader pullback may suggest profit-taking or a tactical reassessment of near-term FDA catalysts and pipeline advancement timelines heading into the final quarter of the year.

PFE declined 1.28% despite carrying a Very Strong Insider Score, per our Insider Score feed, which historically may indicate confidence among insiders in the company's long-term trajectory. JNJ fell 1.42%, while MRK and AMGN shed 1.34% and 1.79%, respectively. LLY, a heavyweight in the diabetes and obesity franchise, also slipped 2.54%, signaling that even high-growth names faced selling pressure. ABBV held relatively steady at +0.16%, while MRNA and GILD posted modest declines of 1.25% and 0.73%.

What May Be Driving the Sector Pullback

Multiple factors could contribute to today's weakness. Reports suggest that investors may be rotating out of positions ahead of earnings season and FDA decision dates slated for late November and December. Pipeline readouts from earlier in the quarter, including Phase III trial outcomes and regulatory guidance updates, have created a mixed backdrop for large-cap drugmakers seeking to balance near-term revenue growth with long-term R&D commitments in obesity, oncology, and immunology.

The contrarian strength in PFE's Insider Score band may suggest that company insiders view the current pullback as tactical rather than fundamental. Investors monitoring biotech and pharma valuations may want to track whether insider buying accelerates at other names in the cohort over the coming weeks, a potential early signal that executives perceive the dip as an entry point.

For a deeper view of insider-buying trends in biotech and pharma, explore our full rankings on the ticker pages and Insider Score feed to identify where conviction may be building among company leadership ahead of fourth-quarter catalysts.